[Federal Register Volume 62, Number 116 (Tuesday, June 17, 1997)]
[Notices]
[Pages 32824-32825]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-15842]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to Section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under Section 1002(a) authorizing the importation of such a 
substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for hearing.
    Therefore, in accordance with Section 1311.42 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on May 19, 1997, 
Wildlife Laboratories, Inc., 1401 Duff Drive, Suite 600, Ft. Collins, 
Colorado 80524, made application by renewal to the Drug Enforcement 
Administration to be registered as an importer of the basic classes of 
controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule         
------------------------------------------------------------------------
Etorphien Hydrochloride (9059).............  II                         
Carfentanil (9743).........................  II                         
------------------------------------------------------------------------

    The firm plans to import the listed controlled substances to 
produce finished products for distribution to its customers. There is 
no domestic source of etorphein hydrochloride or carfentanil.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of these basic classes of controlled substances may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in

[[Page 32825]]

accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 
1316.47.
    Any such comments, objections, or request for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, D.C. 20537, Attention: DEA 
Federal Register Representative (CCR), and must be filed no later than 
(30 days from publication).
    This procedure is to be conducted simultaneously with and 
independent of the procedures in 21 CFR 1311.42 (b), (c), (d), (e), and 
(f). As noted in a previous notice at 40 FR 43745-46 (September 23, 
1975), all applicants for registration to import basic classes of any 
controlled substances in Schedule I or II are and will continue to be 
required to demonstrate to the Deputy Assistant Administrator, Office 
of Diversion Control, Drug Enforcement Administration that the 
requirements for such registration pursuant to 21 U.S.C. 958(a), 21 
U.S.C. 823(a), and 21 CFR 1311.42,(a), (b), (c), (d), (e), and (f) are 
satisfied.

    Dated: June 5, 1997.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 97-15842 Filed 6-16-97; 8:45 am]
BILLING CODE 4410-09-M